Halberd Corporation's Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) has advanced its proprietary technology to Stage 4 in tackling Alzheimer's Disease, a condition impacting over 40 million globally. The company's method aims to eliminate the antibody-disease complex using radiofrequency waves and lasers. Steps 1-3 have been completed, with Step 4 in progress at Youngstown State University, overseen by Dr. William G. Sturrus. Halberd's team is addressing unique challenges to ensure the efficacy of their treatment. The company has expanded its target antigens list, enhancing success probability.

Positive

• Success in completing Steps 1-3 of the Alzheimer's treatment process.
• Current progression to Stage 4 shows commitment to addressing a major health issue.
• Collaboration with Youngstown State University for technical support and development.
• Expanded target antigens list aimed at increasing treatment effectiveness.

Negative

• Challenges persist in developing effective measurement techniques and optimizing particle size.
• No human testing has been conducted yet, delaying potential market entry.

JACKSON CENTER, PA / ACCESSWIRE / June 21, 2021 / Halberd Corporation's (OTC PINK:HALB) proprietary technology enters stage 4 to address Alzheimer's Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer's Disease which afflicts over 40 million people worldwide, equivalent to the combined population of the states of Florida and New York.

The seven (7) stages in Halberd's program are as follows:

1. Identifying target disease(s); (Done)
2. Creating patentable antibodies vs target disease(s); (Done)
3. Combining antibodies with metallic particles; (Done)
4. Eradicating the antibody-disease combination through radiofrequency waves , laser or other proprietary means; (In-process)
5. Conducting animal tests to establish the safety and efficacy; (Preliminary Planning)
6. Conducting human testing
7. Obtaining FDA Certification

Halberd has completed Steps 1-3. Step 4 is underway at Youngstown State University (YSU), under the direction of Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Sciences Department. Dr. Sturrus, stated, "The uniqueness of the methodology and approach has presented some equally unique problems. The team is working to overcome and resolve these challenges. We have had to invent measurement techniques; resolve power, frequency and time exposure issues; particle size optimization; etc. Some of these issues persist, but all of them are being addressed."

William A. Hartman, Halberd's Chairman, President & CEO, commented, "As a team, Halberd and its two state university partners along with GreenBioAZ remain 100% focused on developing an effective treatment for Alzheimer's Disease. Recently we announced the identification of three target antigens to eliminate by our process. After consulting with experts, we have broadened our list of target antigens to include a proprietary list of contributing inflammatory cytokines which increases our probability of success. All of the work Halberd has done to date has laid the foundation for our current program to treat Alzheimer's disease utilizing our patented and patent-pending technologies."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/652434/Halberd-Corporations-Proprietary-Technology-for-Alzheimers-Disease-Enters-Stage-4-of-7-Stage-Process

FAQ

What is Halberd Corporation's recent development regarding Alzheimer's Disease?

Halberd Corporation has advanced to Stage 4 in its program to develop a treatment for Alzheimer's Disease, focusing on eradicating the antibody-disease combination.

What technology is Halberd Corporation using to address Alzheimer's?

Halberd is utilizing proprietary technology involving radiofrequency waves and lasers to target and eliminate disease-related antibodies.

How many stages are in Halberd's Alzheimer's treatment program?

There are seven stages in Halberd's program, with the first three stages already completed and Stage 4 currently in progress.

Where is Halberd Corporation's Alzheimer's research being conducted?

The Alzheimer's research is being conducted at Youngstown State University.

What are the challenges Halberd Corporation faces in its Alzheimer’s program?

Halberd faces unique technical challenges, including developing measurement techniques and optimizing particle sizes.